Douglas Dockery, ScD
Professor of Environmental Epidemiology, Chairman, Department of Environmental Health, Harvard School of Public Health
Professor Doug Dockery, MS, ScD, is Professor of Environmental Epidemiology and Chairman of the Department of Environmental Health at Harvard School of Public Health. Professor Dockery is internationally known for his innovative work in environmental epidemiology, particularly in understanding the relationship between air pollution and respiratory and cardiovascular mortality and morbidity. He was one of the principal investigators of the landmark Six Cities Study of Air Pollution and Health, which showed that people living in communities with higher fine particulate air pollution had shorter life expectancies. Dr. Dockery is currently evaluating the benefits of improved air quality on people’s health. He has been mentor to some of the outstanding investigators in environmental epidemiology including Bert Brunekreef, Annette Peters, Arden Pope, and Joel Schwartz. The International Society for Environmental Epidemiology honored him with its first award for Outstanding Contributions to Environmental Epidemiology in 1999 and the first Best Paper in Environmental Epidemiology Award in 2010.
Charles Henry, PhD
Chuck Henry is a Professor of Chemistry, Chemical & Biological Engineering, and Biomedical Engineering at Colorado State University. He received his Ph.D. in Analytical Chemistry under the supervision of Dr. Ingrid Fritsch at the University of Arkansas, and was an NIH postdoctoral fellow at the University of Kansas under the supervision of Dr. Susan Lunte. His research interests lie broadly in the areas of microscale separations and electrochemistry with application to questions in bioanalytical and environmental chemistry. Specific research projects include developing novel instrumentation for measuring the chemical composition of atmospheric aerosols as well as their biological reactivity, development of biosensors for measuring chemical gradients in biological systems, and creation of inexpensive diagnostic tools for personal exposure assessment. Dr. Henry has published over 75 peer-reviewed publications and sits on the editorial advisory board for Analytica Chimica Acta.
Exposure to environmental pollutants through a range of vectors including the food we eat and the air we breathe results in wide ranging health effects, causing diseases ranging from cancer to asthma attacks. Exposure assessment generally relies on large-scale community level measurements because it reduces the overall measurement burden. Exposure to environmental pollutants, however, is highly dependent on individual activities and thus new tools are needed that allow for personal exposure assessment. This talk will focus on recent work in our laboratory focused on developing paper-based analytical devices for analysis of pollutants in aerosolized particulate matter at the personal level. Paper-based analytical devices provide a low cost and readily portable solution to making personalized exposure measurements. Results for exposure to aerosolized metals in a factory as well as oxidative stress indoor and outdoor air will be discussed.
Catherine Klapperich, PhD
Catherine Klapperich is a Kern Innovation Faculty Fellow and an Associate Professor of Biomedical Engineering at Boston University. She also holds appointments in the Division of Materials Science and Engineering and the Department of Mechanical Engineering. She is the Director of the Laboratory for Diagnostics and Global Healthcare Technologies and a member of theCenter for Nanoscience and Nanotechnology. In 2012, she became the director of the newly formed NIH Center for Future Technologies in Cancer Care (FTCC) at BU.
Before coming to Boston, Dr. Klapperich was a Postdoctoral Fellow at Lawrence Berkeley Laboratory in the lab of Dr. Carolyn Bertozzi, and was a Senior Research Scientist at Aclara Biosciences in Mountain View, CA. She earned her Ph.D. in Mechanical Engineering in 2000 from the University of California, Berkeley with Drs. Lisa Pruitt and Kyriakos Komvopoulos; her M.S. in Engineering Sciences from Harvard University and her B.S. in Materials Science and Engineering from Northwestern University.
Dr. Klapperich’s research is focused on engineering medical devices for use in low resource settings and at the point of care. Current projects are focused on disposable microfluidic diagnostics that incorporate on-board sample preparation and on minimally instrumented devices to enable molecular diagnostics. Her work includes diagnostics for infectious diarrhea, respiratory infections, HIV and other sexually transmitted diseases. These devices have been tested in Nicaragua and Kenya. Other work in the lab is focused on the design and deployment of devices to enable systems biology approaches to studying complex diseases including TB.
Many new and exciting portable molecular testing technologies are emerging for application in both personalized and global medicine. The potential to provide fast, isothermal, and quantitative molecular diagnostic information to clinicians in the field and at the bedside will soon be a reality. What many of these technologies lack is a robust front end for sample clean up and nucleic acid preparation. Such technologies would enable many different downstream molecular assays.
The Klapperich Laboratory for Diagnostics and Global Healthcare Technologies is focused on the design and engineering of manufacturable, disposable systems for low-cost point-of-care molecular diagnostics. We have invented technologies to perform microfluidic sample preparation for bacterial and viral targets from several human body fluids including, urine, blood, stool and nasowash. These technologies include nucleic acid extraction, protein extraction, microorganism enrichment and/or concentration and small-scale dialysis. We are currently working on devices for the detection and quantification of HIV, hemorrhagic fevers, infectious diarrheas, influenza, MRSA and cancer biomarkers.
Projects include detection by PCR, isothermal amplification, and novel optical techniques. Our main application area is global health. We consider assay development, device design, sample flow, storage and transport all opportunities to drive down the cost and increase the accessibility of molecular tests in the developing world.
Konstantina Stankovic, MD, PhD
Konstantina Stankovic, MD, PhD is an auditory neuroscientist and a practicing neurotologic surgeon at the Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital and Harvard Medical School. Her scientific training includes BS degrees in Physics and Biology from Massachusetts Institute of Technology (MIT), PhD degree in Auditory Neuroscience from MIT, and post-doctoral training in Molecular Neuroscience at Harvard. She completed her MD degree, residency in Otolaryngology – Head and Neck Surgery and clinical fellowship in Neurotology at Harvard.
Her present research program is cross disciplinary, and she combines tools of systems neuroscience and optics with molecular, genetic and genomic studies in mice and humans to improve diagnostics and therapeutics for sensorineural hearing loss – the most common sensory deficit worldwide. Her research has been featured by international media, including the Wall Street Journal, Los Angeles Times, Discover Magazine, The Scientist, Quirks and Quarks Canadian Broadcasting Corporation, the Danish Broadcasting Corporation and others.
She has received numerous awards, including the Association of MIT Alumnae (AMITA) award, the Henry Asbury Christian Award from the Harvard Medical School, the Howard Hughes Medical Institute postdoctoral research fellowship, and young investigator award from the National Organization for Hearing Research. She is a member of the executive board and president-elect of the American Auditory Society.
Sensorineural hearing loss is the most common type of hearing loss worldwide, yet the underlying cause is typically unknown because the inner ear cannot be biopsied today without destroying hearing, and intracochlear cells have not been imaged with resolution sufficient to establish diagnosis. In this talk, we describe two recent approaches to advance diagnosis and therapy of sensorineural hearing loss. First, we review our recent collaborative work on powering electronics by the endocochlear potential (EP), which is a battery-like electrochemical gradient found in and actively maintained by the inner ear. At 70–100 mV, the EP is the largest positive direct current electrochemical potential in mammals. We designed and implemented the chip that extracted a minimum of 1.12 nW from the EP of a guinea pig for up to 5 h, enabling a 2.4 GHz radio to transmit measurement of the EP every 40–360 s without affecting hearing. In the future, we envision using the EP to power chemical and molecular sensors, or drug-delivery actuators in the inner era and its vicinity. Second, we describe imaging of the mouse cochlea in situ without exogenous dyes, through a membranous round window, using a near-infrared femtosecond laser as the excitation and endogenous two-photon excitation fluorescence (TPEF) as the contrast mechanisms. We find that TPEF exhibits strong contrast allowing cellular, and even subcellular resolution, and detection of noise-induced pathologic changes. Our results motivate future development of a new and efficient diagnostic tool for intracochlear imaging based on TPEF.
Brian Otis, PhD
Brian Otis received the B.S. degree in electrical engineering from the University of Washington, Seattle, and the M.S./Ph.D. degrees in electrical engineering from UC Berkeley. He is an Associate Professor of Electrical Engineering at the University of Washington and holds a position at Google, Inc. His research interests are low power chip design, micromechanical resonator based clocks, and wireless bioelectrical interface circuits and systems. He has served as an Associate Editor of the IEEE Transactions on Circuits and Systems Part II and is currently a member of the ISSCC Technical Program Committee. Dr. Otis received the U.C. Berkeley Seven Rosen Funds award for innovation in 2003, was co-recipient of the 2002 ISSCC Jack Raper Award for an Outstanding Technology Directions Paper, received the National Science Foundation CAREER award in 2009, and was awarded the University of Washington College of Engineering Junior Faculty Innovator Award in 2011.
Advances in chip and system design will help define the next generation of wireless sensors for biomedical applications. This talk will investigate system and circuit design techniques for body-worn systems, implantable chips, and wireless sensors. These areas present unique challenges at the interface between the IC and the body that cannot be solved by technology scaling alone. Traditional circuit blocks, architectures, and even assembly techniques need to be questioned. Several future applications will demand thin-film realization and biocompatibility of complex systems. RFID-like techniques are highly useful for many of these emerging biomedical applications. We’ll discuss a few examples of the above.
Kevin Dowling, PhD
Vice President R&D, MC10
As Vice-President of Research and Development at MC10, Dr. Dowling is responsible for driving MC10’s high-performance stretchable electronics technology into products and applications. He leads MC10’s efforts in research, engineering, manufacturing as well as intellectual property. Previously, he was Vice President of Strategic Technologies for Philips Color Kinetics, Dr. Dowling was responsible for identifying and developing emerging applications and markets for Color Kinetics technologies. Previously, he joined start-up Color Kinetics as Director of Engineering, leading a team through the design and development of many of Color Kinetics’ most innovative and successful lighting and control products and was a member of the senior management team as CK transitioned through an IPO and later acquisition by Philips.
Prior to Color Kinetics, Dr. Dowling was Chief Robotics Engineer for PRI Automation, the leader in advanced factory automation systems and software for the semiconductor industry. Dr. Dowling has more than 20 years of experience in advanced robotics engineering as a student, Research Engineer and Scientist at the Field Robotics Center of Carnegie Mellon University, where his projects included mobile robot systems for NASA and other sponsors. Dr. Dowling has also consulted for many companies, including Shell Oil and Apple Computer, and was a founding principal of a medical robotics company. He was awarded a NASA Graduate Fellowship for his doctoral program.
Dr. Dowling has over 65 issued US Patents. He serves on the boards of several nonprofit and for-profit organizations and is an advisor to several more. He received his BS degree in Mathematics, and MS and PhD degrees in Robotics all from Carnegie Mellon University.
MC10 reshapes high-performance electronics into human-compatible forms that bend, twist and stretch with the human body. We have developed novel CMOS-compatible fabrication, packaging and integration for applications both in-the-body and on-the-body. The core technology is based on four concepts: extreme device thinning, handling ultra-thin die, flexible metallized interconnects, and embedding devices into elastomers. Each of these concepts is not done in isolation, rather it is the integration of these that enables systems of extraordinary performance. Flexibility, thinness and conformality give whole new capabilities to deploying and quantifying physiological data. We will show several examples, ranging from monitoring internal and external body states to a cardio-vascular applications where electronics are deployed in active hearts.
Florian Solzbacher, PhD
Prof. Solzbacher is Executive Director of the Utah Nanofabrication Laboratory, Co-Director of the Utah Nanotechnology Institute, President and Executive Chairman of Blackrock Microsystems and of Blackrock Neuromed and is a Professor in Electrical and Computer Engineering with adjunct appointments in Materials Science and Bioengineering at the University of Utah. His research focuses on harsh environment microsystems and materials, including implantable, wireless microsystems for biomedical and healthcare applications, and on high temperature and harsh environment compatible micro sensors. Prof. Solzbacher received his M.Sc. EE from the Technical University Berlin in 1997 and his Ph.D. from the Technical University Ilmenau in 2003. He is co-founder of several companies such as Blackrock Microsystems, Blackrock Neuromed, and First Sensor Technology. He was a board member and Chairman of the German Association for Sensor Technology AMA and of Sensor + Test trade show and conference from 2001 until 2009, and serves on a number of company and public private partnership advisory boards and international conference steering committees such as the NIH/NINDS Neural Interfaces Conference. He is author of over 190 journal and conference publications, 5 book chapters and 16 pending patents.
The talk will discuss advances and challenges in developing and translating a chronically implantable, FDA approved electrode/neural interface platform that can be used to obtain high spatial and temporal resolution electrophysiological information from tissue slices through animal models into human patients, while accommodating for the robustness and flexibility constraints of a global research and clinical user community. It will address the often ignored system level approach necessary for successful implementation in vivo, as well as strategies to implement advances in materials, processing and mixed signal/wireless data telemetry technologies into a readily available product.
Joseph Frassica MD
Joe serves on the Philips PCCI executive leadership team as the primary Medical and Technological strategist for our international medical device and informatics organization with 35 major R&D, basic research and manufacturing sites across the globe. Reporting to the CEO in this role he provides medical and technologic leadership for the development of advanced clinical informatics, decision support, Radiology Picture Archive and Communication Systems (PACS), Cardiovascular, Cardiology, Anesthesia, Intensive care and OB and Neonatal clinical information systems, ultrasound information systems, physiologic monitoring applications, Clinical Decision Support (CDS) systems and therapeutic devices including patient ventilators, defibrillators, infant thermoregulatory devices, ECG and anesthesia delivery systems. In addition, he provides primary clinical and technological oversight and guidance for our research related to monitoring, clinical informatics and decision support and therapeutic devices. Our research programs are conducted through our Research and Development programs in Andover MA, and Philips Research in Briarcliff NY, Eindhoven, NL, Shanghai China and Bangalore India as well as with academic and clinical partners around the world. Our current programs are focused on development of advanced predictive algorithms for patient care, the development of intelligent alarm and imaging systems as well as advanced therapeutic monitoring and diagnostic devices.
Immediately prior to joining Philips Healthcare, Joe served as Chief Medical Officer at Holtz Children’s Hospital in Miami, Florida; Chief Medical Information Officer and Executive Medical Director of Aero-Medical Transport for the Jackson Health System; and Associate Chair for Clinical Affairs in the Department of Pediatrics and Professor of Clinical Pediatrics and Anesthesiology at the University of Miami, Miller School of Medicine. In addition to his roles with Philips Healthcare, Joe also serves as Senior Consultant on the Pediatric Critical Care Staff of Massachusetts General Hospital and as Research Affiliate to MIT working closely with Dr Roger Mark’s Laboratory of Computational Physiology.
There are all sorts of innovation around us – we are inundated with new things and technologies daily. But what makes an innovation truly meaningful? Is it the breadth of the change that it inspires? Is it the depth of the impact it has on an individual or group? It is the innovation’s simplicity or is it the beauty of its complexity? We will look at a variety of innovations that have such characteristics and consider their influence on our lives.
John Iafrate, MGH
Dr. Iafrate is a board-certified Pathologist who joined the MGH staff in 2005 and directs a clinical laboratory for molecular diagnostics at MGH and oversees a translational research laboratory that supports both Pathology and the MGH Cancer Center. He is an MD-PhD having received his dual degree from the State University of New York at Stony Brook in 2000 and was trained in Anatomic and Molecular Genetic Pathology at Brigham and Women’s Hospital. His post-doctoral work involved the discovery and description of a novel source of human genetic diversity termed copy number variation (CNV). Since arriving at MGH, he has established a cancer diagnostics lab focusing on genetic fingerprints that help guide novel “targeted” therapies. His laboratory launched Snapshot several years ago, an assay that tests over 100 of the most common mutations in tumors. His research is focused on lung and brain tumors, and he has been closely involved in the clinical development of crizotinib and companion diagnostics in ALK-positive lung cancers.
James S. Michaelson Ph.D.
James Michaelson PhD is an Associate Professor of Pathology in the Departments of Pathology and Surgery at the Massachusetts General Hospital, and the Department of Pathology, Harvard Medical School, Boston, MA. He received his Doctorate in Biology at Cornell University and Postdoctoral Training in Immunogenetics at the Memorial Sloan-Kettering Institute. His research concerns the collection of data, and the development of mathematical methods for predicting cancer outcome, the analysis of large cancer datasets for characterizing medical usage for the purpose of improving care and lowering cost, the analysis of cancer screening and other preventive health services, the development of imaging methods for analyzing cancer specimens, and the use of modern computer speech and telephony to design systems that increase patient compliance.
For the past decade, the work of my group has been concerned with building very large databases on patients, using this information to understand disease, and especially cancer, and its treatment, using mathematics to answer practical questions about health, and building web-based tools for communicating this information to patients and medical professionals (the CancerMath.net and PreventiveMath.net calculators).
Dr. Michael Cima
Dr. Michael J. Cima is a Professor of Materials Science and Engineering at the Massachusetts Institute of Technology and has an appointment at the David H. Koch Institute for Integrative Cancer Research. He was elected a Fellow of the American Ceramics Society in 1997. Prof. Cima was elected to the National Academy of Engineering in 2011. He now holds the David H. Koch Chair of Engineering at MIT. He was appointed faculty director of the Lemelson-MIT Program in 2009 which is a program to inspire youth to be inventive and has a nationwide reach. Prof. Cima is author or co-author of over two hundred peer reviewed scientific publications, over forty US patents, and is a recognized expert in the field of materials processing. Prof. Cima is actively involved in materials and engineered systems for improvement in human health such as treatments for cancer, metabolic diseases, trauma, and urological disorders. Prof. Cima’s research concerns advanced forming technology such as for complex macro and micro devices, colloid science, MEMS and other micro components for medical devices that are used for drug delivery and diagnostics, high-throughput development methods for formulations of materials and pharmaceutical formulations. He is a coinventor of MIT’s three dimensional printing process. His research has led to the development of chemically derived epitaxial oxide films for HTSC coated conductors. He and collaborators are developing implantable MEMS devices for unprecedented control in the delivery of pharmaceuticals and implantable diagnostic systems. Finally, through his consulting work he has been a major contributor to the development of high throughput systems for discovery of novel crystal forms and formulations of pharmaceuticals. Prof. Cima also has extensive entrepreneurial experience. He is co-founder of MicroChips Inc., a developer of microelectronic based drug delivery and diagnostic systems. Prof. Cima took two sabbaticals to act as senior consultant and management team member at Transform Pharmaceuticals Inc. a company that he helped start and that was ultimately acquired by Johnson and Johnson Corporation. He is a co-founder and director at T2 Biosystems a medical diagnostics company. Most recently, Prof. Cima co-founded SpringLeaf Therapeutics a specialty pharmaceutical company and Taris Biomedical a urology products company.
Biopsies provide required information to diagnose cancer but, because of their invasiveness, they are difficult to use for managing cancer therapy. The ability to repeatedly sample the local environment for tumor biomarker, chemotherapeutic agent, and tumor metabolite concentrations could improve early detection of metastasis and personalized therapy. The Cima Laboratory has developed an implantable diagnostic device that senses the local in vivo environment. This device, which can be left behind during biopsy and interrogated at later times using noninvasive magnetic relaxation techniques. Recent research has, for example, revealed intratumoral pH as an early indicator of tumor progression and response to chemotherapy. Intratumoral pO2 has also been shown to be an important prognostic factor for radiotherapy outcomes. Existing technology that assesses treatment efficacy is cumbersome, costly and, in some cases, invasive. This project aims to radically transform clinical practice by enabling rapid, accurate, continuous, and non-invasive determination of tumor pH and pO2. I will report on several approaches. The first is a polymer solid-state contrast agent for oxygen determination using MRI which can be implanted with a syringe or biopsy needle. The second is a millimeter-sized NMR probe that can be implanted using a biopsy needle. The 15 MHz probe measures 2 mm in diameter and 6 mm in length and has a 10 μL cavity. The probe encapsulates NMR contrast agents that are sensitive to local changes in pH and oxygen in a tumor. Excitation and readout are achieved wirelessly through weak magnetic coupling to a second resonant coil. A commercial single-sided magnet provides the static field.
Christopher J. Neil
Senior Vice President, Industrial and Medical Solutions Group
As Senior Vice President, Chris Neil is responsible for definition, development, and marketing of products and solutions addressing the industrial and medical end markets. He joined Maxim in 1990 and became a Vice President in 2006. Mr. Neil has a wide range of experience gained from managing diverse business activities for Maxim in the consumer, communications, computing, and industrial markets. These different businesses reflect Maxim’s wide range of product offerings, the broad skill set of its work force, and its diverse customer base.
Mr. Neil has drawn on his broad experience to propose and implement several important initiatives. He was among the first to articulate Maxim’s unique balanced business model, by which Maxim routinely reassesses and rebalances its investments in the computer, consumer, industrial, and communications markets. In this way the company better manages its long-term growth and long-term profitability. He also drove several acquisitions which built on Maxim’s embedded microcontroller expertise and strengthened the company’s position as a complete systems solutions provider, especially in the smart grid and secure financial transactions markets. He is the driving force behind the company’s current mission to extend Maxim’s reach to an even wider customer base in the industrial and medical markets. Mr. Neil continues to drive organizational, R&D management, and marketing changes that promote collaboration and take full advantage of the deep talent pool of the entire Maxim team. Mr. Neil holds BSEE and MSEE degrees from the Massachusetts Institute of Technology.
Joseph F. Coughlin
MIT Engineering Systems Division & Director, MIT AgeLab
Joseph F. Coughlin is Director of the Massachusetts Institute of Technology AgeLab. His research provides insights on how demographic change, technology, social trends and consumer behavior will converge to drive future innovations in business and government. Based in MIT’s Engineering Systems Division he teaches policy and planning and is one of Fast Company Magazine’s ‘100 Most Creative People in Business’. He was named by the Wall Street Journal as one of “12 pioneers inventing the future of retirement and how we will all live, work and play tomorrow.” Coughlin is a Behavioral Sciences Fellow of the Gerontological Society of America and a Fellow of Switzerland’s World Demographics & Ageing Forum advising and speaking to businesses, governments and non-profits worldwide. He has served numerous advisory boards including those for British Telecom Health and the Gallup-Healthways Well-Being Index Scientific Advisory Board. He was appointed by President Bush to the White House Conference on Aging Advisory Committee serving on its Market Innovations Sub-Committee. He is a regular contributor to WSJ/MarketWatch, Huffington Post and his own blog Disruptive Demographics on BigThink.com. Prior to MIT he was with EG&G a Fortune 1000 science & technology firm consulting to business and government worldwide.
The fastest growing population in Europe, North America and many Asian nations, including China, are people over 60 years old. More than sheer numbers this population is placing new demands on healthcare services and has even greater expectations to live longer better. How will old age and new technology converge to meet increasing healthcare needs, public-private costs and related delivery challenges? This presentation will identify evolving patterns in consumer behavior and technology that will drive innovative technology-enabled service models that may potentially meet the demands of an aging society, manage public-private payer costs and produce improved well-being outcomes.
James J. Collins is an Investigator of the Howard Hughes Medical Institute, and a William F. Warren Distinguished Professor, University Professor, Professor of Biomedical Engineering, Professor of Medicine and Co-Director of the Center for BioDynamics at Boston University. He is also a core founding faculty member of the Wyss Institute for Biologically Inspired Engineering at Harvard University. His research group works in synthetic biology and systems biology, with a particular focus on using network biology approaches to study antibiotic action, bacterial defense mechanisms, and the emergence of resistance. Professor Collins’ patented technologies have been licensed by over 25 biotech, pharma and medical devices companies, and he has helped to launched a number of companies, including Sample6 Technologies and EnBiotix. He has received numerous awards and honors, including a Rhodes Scholarship, a MacArthur “Genius” Award, an NIH Director’s Pioneer Award, a Sanofi-Institut Pasteur Award, as well as several teaching awards. Professor Collins is an elected member of the National Academy of Engineering, the Institute of Medicine, and the American Academy of Arts & Sciences, and a charter fellow of the National Academy of Inventors.
Traditionally, noise has been viewed as a detriment to signal detection and information transmission. However, it has been shown that noise can enhance the detection and transmission of weak signals in certain nonlinear systems, via a mechanism known as stochastic resonance (SR). In this talk, we describe studies wherein we demonstrate SR-type behavior in model neurons, rat cutaneous afferents and human sensorimotor function. We show that reduced vibrotactile sensitivity in older adults, patients with stroke, and patients with diabetic neuropathy can be significantly improved with input mechanical noise. We also demonstrate that the application of sub-sensory mechanical noise to the soles of the feet via vibrating insoles improves balance control in healthy young subjects, older adults, patients with diabetic neuropathy, and patients with stroke. We discuss how noise-based techniques and devices might prove useful in overcoming age- and disease-related losses in sensorimotor function, as well as enhancing human performance in athletics.
Bruce D. Levy, M.D.
Bruce D. Levy, M.D. is an Associate Professor of Medicine at Harvard Medical School, currently serving as Director of Academics and Career Development for the Medical Residency at Brigham and Women’s Hospital. Dr. Levy has written or co-authored over 100 original peer-reviewed manuscripts, reviews and book chapters and over 10 published patents. By applying cutting edge advances in lipid biochemistry and molecular biological techniques, Dr. Levy has made key contributions towards unraveling cellular and molecular mechanisms for catabasis, in particular after lung inflammation, injury and infection. His work already offers the promise of new approaches to the management of asthma, COPD and ARDS. Dr. Levy has been the recipient of numerous grant awards from the National Institutes of Health, including several grants on topics related to counter-regulatory lipid signals in lung disease and their translation to asthma and ARDS. Since 2003, he has served in many capacities as a grant reviewer for the NIH. Since 2009, Dr. Levy has also served the American Thoracic Society as an Associate Editor for the American Journal of Respiratory and Critical Care Medicine, the leading journal in the subspecialty, and as an Associate Editor for the New England Journal of Medicine for its award-winning clinical problem solving series.
Acute respiratory distress syndrome (ARDS) is a devastating disorder caused by many underlying medical and surgical diseases. Key features of ARDS include: (a) respiratory distress and tachypnea (b) severe hypoxemia (c) diffuse alveolar infiltrates on chest radiography and (d) decreased lung compliance, all occurring in the setting of an acute medical or surgical illness. Approximately 11% of all ICU admissions (including community and tertiary care centers) suffer from acute respiratory failure, with ~20% of these patients meeting criteria for ARDS. It is estimated that about 1 out of every 50 patients admitted to intensive care units will suffer from ARDS, and the incidence is predicted to rapidly rise over the next decade. Currently, there are no known effective medical therapies, so patients are supported on ventilators in the ICU for the duration of their critical illness. Innovation is desperately needed to more effectively monitor patients with ARDS and more efficiently deliver oxygen to these critically ill patients.
Dr. Jongyoon Han is currently an associate professor in the Department of Electrical Engineering and Computer Science and the Department of Biological Engineering, Massachusetts Institute of Technology. He received B.S.(1992) and M.S.(1994) degree in physics from Seoul National University, Seoul, Korea, and Ph.D. degree in applied physics from Cornell University in 2001. He was a research scientist in Sandia National Laboratories (Livermore, CA), until he joined the MIT faculty in 2002. He received NSF CAREER award (2003) and Analytical Chemistry Young Innovator Award (ACS, 2009). His research is mainly focused on applying micro/nanofabrication techniques to various problems, such as biosample preparation, biodetection, desalination / water purification, and even neurotechnology.
A recent new direction in blood diagnostics is the idea of using various cells circulating in blood stream as a ‘window’ to physiological conditions. I will discuss several ‘blood cell diagnostics’ examples from our group’s research. Recent advances in high volume throughput cell separation techniques enable the enrichment of even lowest abundance cells in blood, therefore allowing the recovery of extremely rare cells such as circulating tumor cells (CTCs), blood-borne bacteria, and others. Separation by inertial microfluidics is based on cells’ biophysical properties but not chemical labels, therefore enabling various downstream assays of these recovered cells. In addition, cell deformability of red blood cells (RBCs) are now emerging as an important indicator for many different pathophysiological situations, including malaria, sepsis, and others. In our group, we developed a ‘spleen mimic’ microfluidic model system to measure and characterize the RBCs’ ability to survive splenic clearance, which has important implication in many diseases. These and other recent examples of using blood cells as diagnostic unit have the potential to overcome specificity limitations of previous molecular blood diagnostics.
Dr. Lowery was the first person to join T2 Biosystems in 2007 working closely with the Founders in the early stages of the company. He has applied his experience in cutting-edge biochemical and biophysical method development to play a key role in the establishing T2MR as an industry-leading technology. Dr. Lowery is also integral in driving the company’s product strategy and development. He has successfully led internal research and development efforts to significantly advance T2MR as a leading technology through innovative and proprietary solutions. Prior to joining T2 Bio Dr. Lowery attained a Ph.D. in Chemistry from the University of California Berkeley and a BS in Honors Biochemistry from Brigham Young University.
T2HemoStat is a new approach using T2 magnetic resonance (T2MR) that allows for rapidly identifying and monitoring impaired hemostasis, prothrombotic states and fibrinolysis on a small, portable instrument using finger-prick volumes of blood. T2MR measures complex hemostasis phenomena in a reagent-free manner, using only standard activators and water present in the blood or plasma sample. This talk will introduce T2MR for Hemostasis measurements and report on use in pre-clinical studies for established coagulation measures (PT, HCT, Platelet activity & inhibition), novel hemostasis biomarkers (prothrombotic states, fibrinolysis), and therapeutic monitoring (Plavix, fibrinolytic agents).